Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowPfizer (PFE) stock is down over 50% from its 2021 high as demand for COVID vaccines decreases. The company is facing headwinds, including upcoming patent cliffs that could lead to revenue declines for key drugs. Despite this, Pfizer maintains a 6.4% dividend yield, with management stating that supporting the dividend is a key corporate goal. The company has taken steps to pivot towards GLP-1 weight-loss drugs and continues to develop its portfolio in oncology and migraine treatments, which could improve its market position in the future.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Pfizer Inc. (PFE)
Pfizer is one of the world’s largest pharmaceutical companies, developing vaccines and medicines across many therapeutic areas.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier PFE news
- Pfizer (PFE) Receives FDA Approval for Veppanu Breast Cancer Drug
- Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
- Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
- Pfizer Seeks FDA Approval for Lyme Disease Vaccine with 70% Efficacy
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
